HX575 epoetin alfa

Phase 3Small molecule

Novartis

HX575 epoetin alfa is one of 109 small molecule programs targeting Anemia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

108

Competitors

Pipeline

Status by Indication[3][1]

Indication

AnemiaActive, not recruiting

Chronic Kidney DiseaseActive, not recruiting

Renal InsufficiencyActive, not recruiting

AnemiaPhase 3

Active, not recruiting

Chronic Kidney DiseasePhase 3

Active, not recruiting

Renal InsufficiencyPhase 3

Active, not recruiting

Competition

Competitive Landscape

540 competitors in Chronic Kidney Disease

#DrugCompanyPhaseTrials

Aranesp

Amgen

Preclinical

40 2

HX575 epoetin alfa

Novartis

Phase 3

2 3

Glucotrol

Pfizer

Preclinical

1 4

Vemlidy

Gilead

Preclinical

1 5

Flomax

Epoetin Beta

5 7

PROCRIT

WWim Janssens

Preclinical

1 8

Genotropin

EMD Serono

Preclinical

1 9

Viagra

VViatris Specialty LLC

Preclinical

1 10

Ativan

BBausch Health Americas, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Kidney Disease2 trials

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)

Completed· Novartis logo

Novartis·Phase 3·NCT01576341·417 enrolled

Study to Evaluate the Efficacy, Safety and Immunogenicity of Subcutaneous HX575 in the Treatment of Anemia Associated With Chronic Kidney Disease (SWEEP)

Withdrawn· Novartis logo

Novartis·Phase 3·NCT00869856

Safety and Efficacy1 trial

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

Completed· Novartis logo

Novartis·Phase 3·NCT01693029·435 enrolled

Anemia1 trial

Study to Evaluate the Efficacy and Safety of HX575 Hexal AG vs ERYPO® for the Treatment of Anemia in Hemodialysis Patients

Completed· Novartis logo

Novartis·Phase 3·NCT00666835·478 enrolled

CKD1 trial

Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.

Completed· Novartis logo

Novartis·Phase 4·NCT00632125·1,695 enrolled

Renal insufficiency1 trial

Randomized, Controlled, Double-blind Multicenter Safety Study to Evaluate the Safety and Immunogenicity of Subcutaneous EPO HEXAL vs. ERYPO® in the Treatment of Anemia Associated With Chronic Renal Insufficiency in Predialysis Patients

Terminated· Novartis logo

Novartis·Phase 3·NCT00701714·337 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for HX575 epoetin alfa. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HX575 epoetin alfa compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HX575 epoetin alfa. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Novartis

HX575 epoetin alfa

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Chronic Kidney Disease2 trials

Safety and Efficacy1 trial

Anemia1 trial

CKD1 trial

Renal insufficiency1 trial

References

Drug Info

Quick Facts

Related News